PATENT CLAIM ANALYSIS

Application Number: 15770737
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "356000"]

Abstract:
The present specification provides methods of treating nervous system disorders with a thyroid hormone neutral dose of a RXR agonist to promote remyelination or neuroprotection or both and thereby maintain or regenerate healthy axons and neurons.

Claim (Index 27):
A method of treating a nervous system disorder, the method comprising:\n administering to an subject in need thereof a thyroid hormone neutral dose of 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E) heptadienoic acid; wherein administration of the thyroid hormone neutral amount of the RXR agonist treats the CNS disorder in the subject; wherein the RXR agonist is delivered directly to the CNS of the subject by intrathecal administration, epidural administration, cranial injection or implant, or nasal administration; and wherein the thyroid hormone neutral dose of RXR agonist results in an improved efficacy in the individual as compared to a dose of the RXR agonist which causes a substantial decrease in plasma T4 levels.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 91.0
- Lexical Diversity: 1.15625
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15812821', '15339752', '15339762', '14507730', '10477876']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.839477137798112
- 35 USC 102 Novelty (BERT): 0.6485549842572368
- Combined Prediction Score: 0.8203849224440245
- Mean Citation Score: 525.456226
- Max Citation Score: 623.54266
- Similarity Product: 564.7190784829091

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test